EICHORCondition: Invasive Aspergillosis · Invasive Pulmonary Aspergillosis · Sponsor: Vical
The purpose of the trial is to evaluate the safety and efficacy of a new antifungal with a novel mechanism of action in immunocompromised adults with invasive aspergillosis.
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
| University of Alabama at Birmingham Hospital, Division of Infectious Diseases | Birmingham, Alabama, United States | — |
| UC San Diego Moores Cancer Center | La Jolla, California, United States | — |
| UC Davis Health, Dept. of Internal Medicine, Div. of Infectious Diseases | Sacramento, California, United States | — |
| Christiana Care Health Services, Department of Medicine | Newark, Delaware, United States | — |
| Medical College of Georgia at Augusta University | Augusta, Georgia, United States | — |
| DMC Harper University Hospital | Detroit, Michigan, United States | — |
| University of Minnesota, Department of Medicine | Minneapolis, Minnesota, United States | — |
| Washington University School of Medicine, Division of Infectious Disease | St Louis, Missouri, United States | — |
| The University of Texas Health Science Center, Department of Internal Medicine | Houston, Texas, United States | — |
| Fred Hutchinson Cancer Research Center (FHCRC) | Seattle, Washington, United States | — |
| Medical College of Wisconsin | Milwaukee, Wisconsin, United States | — |
| University Hospital Antwerp (UZA), Department of Hematology | Edegem, Antwerp, Belgium | — |
+ 16 more locations — full list on the registry record.
Sponsor or site team? See the site landscape for this trial — listed sites, countries, and recruiting-density context.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03327727